A study of ADX-102 for the treatment of Sjögren-Larsson Syndrome.

Trial Profile

A study of ADX-102 for the treatment of Sjögren-Larsson Syndrome.

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Reproxalap (Primary)
  • Indications Sjogren-Larsson syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Aldeyra Therapeutics
  • Most Recent Events

    • 09 Nov 2017 According to an Aldeyra Therapeutics media release, this trial is expected to begin in the first half of 2018. Results are expected to be announced in the second half of 2018.
    • 15 May 2017 According to an Aldeyra Therapeutics media release, data from part-1 of this trial will be used to confirm statistical power for part-2, and are expected to be available in the second half of 2018.
    • 20 Apr 2017 According to an Aldeyra Therapeutics media release, this trial is expected to begin later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top